SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biotechnology & Drugs
An SI Board Since February 2001
Posts SubjectMarks Bans
232 7 0
Emcee:  2MAR$ Type:  Moderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
182BGEN ($33-$35) PE20 profit falls as sales of flagship drug slow, QTR in-line $52MAR$-10/18/2002
181IDEC $39-$41-?) third-quarter profit rises 42 pct Wednesday October 16, 6:12 pm2MAR$-10/16/2002
180VRTX) results on Monday, November 4, 2002 A/H2MAR$-10/15/2002
179AFFX will release 3rd qtr results for 2002 after market on Weds, Oct 23. stockc2MAR$-10/14/2002
17810/1/02 Myriad Genetics <MYGN> Morgan Stanley Overweight $34Frederick Langford-10/1/2002
177I think that even in Bio-tech, investors are going to be more selective now. ThX Y Zebra-10/1/2002
176Biotech Ends Q3 02 with a Whimper Investors Are Waiting ... But S2MAR$-10/1/2002
175under this environment... I wonder if positive news would help to those companiX Y Zebra-9/30/2002
174IDEC CFO Schneider to retire, interim CFO named Monday September 30, 7:32 pm ET2MAR$-9/30/2002
173IDEC Pharmaceuticals and Nippon Shinyaku Sign License Agreement to Develop Novel2MAR$-9/30/2002
172Genzyme General Files to Market Cholestagel(R) in Europe PR NEWSWIRE - SeptemberX Y Zebra-9/26/2002
171UPDATE 3-Lilly gets conditional nod for depression drug (adds closing stock pr2MAR$-9/16/2002
170CEPH Announces Positive Results from a Study of PROVIGIL in Children with Attent2MAR$-9/16/2002
169GENZ revising EPS , $1.05-$1.11bil from $1.10-$1.15 biz.yahoo.com <i> Th2MAR$-9/16/2002
168Sept 26th...GENZ, FDA meeting on licensing of Fabrazyme. and then the next day,SusieQ1065-9/15/2002
16708:37 ET BGEN Biogen: 6-month review could limit Amevive sales, boost Enbrel SusieQ1065-9/13/2002
166DNA's pipeline could have some clogs.. thestreet.comSusieQ1065-9/12/2002
165Biogen's AMEVIVE(R) (Alefacept) Application on Track for Early 2003 Approval2MAR$-9/12/2002
16407:11 ET DNA Genentech Avastin trials does not meet endpoint (32.00) AnnounSusieQ1065-9/10/2002
16315:14 ET Thomas Weisel on biotech Thomas Weisel believes that today's aSusieQ1065-9/8/2002
162Genelabs (GNLB +90% $2.50) Gets conditional FDA Approvable Letter for Prestara 2MAR$-8/30/2002
161InterMune ITMN Up 13% Despite Drug's Partial Failure In Trial online.wsj.co2MAR$-8/28/2002
160oh..i just woke up...can't believe i overslept this.. can't send PM'SusieQ1065-8/28/2002
159from 8/15 ...(MEDI) Cap=$6Bil eps =-$4.25 ...29.18 -0.61: Co lowers its Q3 guida2MAR$-8/28/2002
158From 8/7 ....Solly examines stock option expensing for biotech : Salomon Smith B2MAR$-8/28/2002
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News